Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

133.53 +2.01 (+1.53%)
Streaming Delayed Price Updated: 11:42 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 705,646
Open 131.47
Bid (Size) 133.47 (4)
Ask (Size) 133.60 (2)
Prev. Close 131.52
Today's Range 131.00 - 135.31
52wk Range 74.75 - 142.00
Shares Outstanding 96,748,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
Today’s episode of Full Court Finance at Zacks dives into the recent stock market pullback. We then turn our attention to three innovators in their respective industries—Vertiv, Align Technology, and... 
Via Talk Markets
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily

Performance

YTD
+8.49%
+8.49%
1 Month
-4.69%
-4.69%
3 Month
+3.28%
+3.28%
6 Month
+55.24%
+55.24%
1 Year
+7.84%
+7.84%

More News

Read More
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape
Via InvestorPlace
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Via Benzinga
DexCom Inc Chart Analysis
Via Talk Markets
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Via InvestorPlace
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
Via Investor's Business Daily
2 Growth Stocks to Buy Hand Over Fist in April
Via The Motley Fool
7 Nasdaq Stocks to Sell in April Before They Crash & Burn
Via InvestorPlace
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
Via MarketBeat
3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List
Via InvestorPlace
Topics Stocks
Exposures US Equities
Micron, Dropbox And 2 Other Stocks Insiders Are Selling
Via Benzinga
Market Cap Game Show: Andy Cross vs. Bill Mann
Via The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Via Investor's Business Daily
Two Hot AI Stocks Lead S&P 500 Monday
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
Via InvestorPlace
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.